FDA approves Linzess for irritable bowel syndrome, constipation

Updated:

HealthMore>>
Genes may boost woman's risk of postpartum depression
Genes may boost woman's risk of postpartum depression
Pregnant women with specific alterations in two genes may be at increased risk of suffering depression after giving birth, a small new study suggests.More >>
Pregnant women with specific alterations in two genes may be at increased risk of suffering depression after giving birth, a small new study suggests.More >>
Racial disparities seen in U.S. lung cancer treatment
Racial disparities seen in U.S. lung cancer treatment
Racial disparities exist in the treatment of non-small cell lung cancer among hospitals in the United States, according to a large new study.More >>
Racial disparities exist in the treatment of non-small cell lung cancer among hospitals in the United States, according to a large new study.More >>
Favorite music may ease anxiety for patients
Favorite music may ease anxiety for patients
Music can help soothe the fear and anxiety of critically ill patients who have been placed on ventilators, reducing both their stress and their need for sedatives, according to a new study.More >>
Music can help soothe the fear and anxiety of critically ill patients who have been placed on ventilators, reducing both their stress and their need for sedatives, according to a new study.More >>

THURSDAY, Aug. 30 (HealthDay News) -- Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome accompanied by constipation, the agency said Thursday in a news release.

The National Institutes of Health estimates that some 63 million people are affected by chronic constipation, and about 15.3 million have irritable bowel syndrome (IBS), the FDA said.

Linzess is taken once daily on an empty stomach, at least 30 minutes before the first meal. The most frequently noted adverse reaction is diarrhea.

The drug's label contains a boxed warning that it shouldn't be taken by people aged 16 or younger, the FDA said.

Linzess is produced by Cambridge, Mass.-based Ironwood Pharmaceuticals.

More information

Medline Plus has more about constipation.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.

FDA approves Linzess for irritable bowel syndrome, constipation - NBC Right Now/KNDO/KNDU Tri-Cities, Yakima, WA |

FDA approves Linzess for irritable bowel syndrome, constipation

HealthMore>>

Genes may boost woman's risk of postpartum depression

Genes may boost woman's risk of postpartum depression

Racial disparities seen in U.S. lung cancer treatment

Racial disparities seen in U.S. lung cancer treatment

Favorite music may ease anxiety for patients

Favorite music may ease anxiety for patients